Why the study?
Does perioperative beta-blocker administration reduce adverse cardiac events and mortality in patients with cardiac risk factors undergoing major noncardiac surgery?
Does perioperative beta-blocker administration reduce adverse cardiac events and mortality in patients with cardiac risk factors undergoing major noncardiac surgery?
Provides practical, case-based guidance on the perioperative use of beta-blockers to reduce cardiac risk in patients undergoing noncardiac surgery.
May inform individualized perioperative beta-blocker decisions; leaves open the need for updated trials in contemporary practice.
Recent studies suggest that beta-blockers administered perioperatively may reduce the risk of adverse cardiac events and mortality in patients who have cardiac risk factors and undergo major noncardiac surgery. The objective of this article is to provide practicing physicians with examples of perioperative beta-blocker use in practice by using several hypothetical cases. Although current evidence describing the effectiveness of perioperative beta-blockade may not address all possible clinical situations, it is possible to formulate an evidence-based approach that will maximize benefit to patients. We describe how information from several sources can be used to guide management of patients with limited exercise tolerance, those at highest risk for perioperative cardiac events, patients who are taking beta-blockers long-term, and those with relative contraindications to beta-blockade. Even though fine points of their use remain to be elucidated, perioperative beta-blocker use is important and can be easily applied in practice by any physician involved with the care of patients perioperatively.
No takes yet. Share an insight, caveat, or question.
Auerbach et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: